ARCALYST
Preclinical
RegeneronARCALYST is one of 27 therapeutic programs targeting Cryopyrin-Associated Periodic Syndrome. It is currently in Preclinical.
2
Indications
0
Total Trials
0
Active Trials
26
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
25 competitors in Gout
#DrugCompanyPhaseTrials
1Uloric
TakedaApproved
Zyloprim
Jazz PharmaceuticalsApproved
Colcrys
Jazz PharmaceuticalsApproved
Trexall
Jazz PharmaceuticalsApproved
Aleve
Jazz PharmaceuticalsApproved
Cellcept
RocheApproved
Prevacid
TakedaApproved
Otezla
AmgenApproved
Rayos
RRoxane Laboratories
Approved
Glucophage
EMD SeronoApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for ARCALYST. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company